A Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma

Trial Profile

A Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs IMC gp100 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Immunocore
  • Most Recent Events

    • 23 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 30 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Feb 2017.
    • 30 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top